| Hemophilia B gene therapy with a high-specific-activity factor IX variant LA George, SK Sullivan, A Giermasz, JEJ Rasko, BJ Samelson-Jones, ... New England Journal of Medicine 377 (23), 2215-2227, 2017 | 785 | 2017 |
| Multiyear factor VIII expression after AAV gene transfer for hemophilia A LA George, PE Monahan, ME Eyster, SK Sullivan, MV Ragni, SE Croteau, ... New England Journal of Medicine 385 (21), 1961-1973, 2021 | 193 | 2021 |
| Long-term follow-up of the first in human intravascular delivery of AAV for gene transfer: AAV2-hFIX16 for severe hemophilia B LA George, MV Ragni, JEJ Rasko, LJ Raffini, BJ Samelson-Jones, ... Molecular Therapy 28 (9), 2073-2082, 2020 | 166 | 2020 |
| Novel approaches to hemophilia therapy: successes and challenges VR Arruda, BS Doshi, BJ Samelson-Jones Blood, The Journal of the American Society of Hematology 130 (21), 2251-2256, 2017 | 129 | 2017 |
| Interactions between nitric oxide and indoleamine 2, 3-dioxygenase BJ Samelson-Jones, SR Yeh Biochemistry 45 (28), 8527-8538, 2006 | 93 | 2006 |
| Adeno-associated virus gene therapy for hemophilia BJ Samelson-Jones, LA George Annual review of medicine 74 (1), 231-247, 2023 | 82 | 2023 |
| Gene therapy for immune tolerance induction in hemophilia with inhibitors VR Arruda, BJ Samelson‐Jones Journal of Thrombosis and Haemostasis 14 (6), 1121-1134, 2016 | 67 | 2016 |
| Protein-engineered coagulation factors for hemophilia gene therapy BJ Samelson-Jones, VR Arruda Molecular Therapy-Methods & Clinical Development 12, 184-201, 2019 | 61 | 2019 |
| A phase 1/2 trial of investigational Spk-8011 in hemophilia a demonstrates durable expression and prevention of bleeds KA High, LA George, ME Eyster, SK Sullivan, MV Ragni, SE Croteau, ... Blood, The Journal of the American Society of Hematology 132 (Supplement 1 …, 2018 | 61 | 2018 |
| Obstacles and future of gene therapy for hemophilia VR Arruda, BJ Samelson-Jones Expert opinion on orphan drugs 3 (9), 997-1010, 2015 | 51 | 2015 |
| Hyperactivity of factor IX Padua (R338L) depends on factor VIIIa cofactor activity BJ Samelson-Jones, JD Finn, LA George, RM Camire, VR Arruda JCI insight 4 (14), 2019 | 46 | 2019 |
| Timing of intensive immunosuppression impacts risk of transgene antibodies after AAV gene therapy in nonhuman primates BJ Samelson-Jones, JD Finn, P Favaro, JF Wright, VR Arruda Molecular Therapy Methods & Clinical Development 17, 1129-1138, 2020 | 45 | 2020 |
| Emerging therapies for hemophilia: controversies and unanswered questions VR Arruda, BS Doshi, BJ Samelson-Jones F1000Research 7, 2018 | 41 | 2018 |
| Circumventing furin enhances factor VIII biological activity and ameliorates bleeding phenotypes in hemophilia models JI Siner, BJ Samelson-Jones, JM Crudele, RA French, BJ Lee, S Zhou, ... JCI insight 1 (16), 2016 | 36 | 2016 |
| Spk-8011: preliminary results from a phase 1/2 dose escalation trial of an investigational AAV-mediated gene therapy for hemophilia A LA George, MV Ragni, BJ Samelson-Jones, A Cuker, AR Runoski, G Cole, ... Blood 130, 604, 2017 | 35 | 2017 |
| Efficacy and safety in 15 hemophilia B patients treated with the AAV gene therapy vector fidanacogene elaparvovec and followed for at least 1 year LA George, SK Sullivan, JEJ Rasko, A Giermasz, BJ Samelson-Jones, ... Blood 134, 3347, 2019 | 32 | 2019 |
| Follow-up of more than 5 years in a cohort of patients with hemophilia B treated with fidanacogene elaparvovec adeno-associated virus gene therapy BJ Samelson-Jones, SK Sullivan, JEJ Rasko, A Giermasz, LA George, ... Blood 138, 3975, 2021 | 31 | 2021 |
| Translational potential of immune tolerance induction by AAV liver-directed factor VIII gene therapy for hemophilia A BJ Samelson-Jones, VR Arruda Frontiers in Immunology 11, 618, 2020 | 31 | 2020 |
| Activated protein C has a regulatory role in factor VIII function AR Wilhelm, NA Parsons, BJ Samelson-Jones, RJ Davidson, CT Esmon, ... Blood, The Journal of the American Society of Hematology 137 (18), 2532-2543, 2021 | 29 | 2021 |
| Evolutionary insights into coagulation factor IX Padua and other high-specific-activity variants BJ Samelson-Jones, JD Finn, LJ Raffini, EP Merricks, RM Camire, ... Blood Advances 5 (5), 1324-1332, 2021 | 26 | 2021 |
J Fraser WrightStanford UniversityCorreu electrònic verificat a stanford.edu
